Deutsch English Français

Contact

EP3296317

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP3296317

EP3296317 - TOPK PEPTIDES AND VACCINES INCLUDING THE SAME [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 16.10.2020 Database last updated on 11.09.2024
Former	The patent has been granted Status updated on 08.11.2019
Former	Grant of patent is intended Status updated on 11.07.2019
Former	Examination is in progress Status updated on 01.06.2019
Former	Grant of patent is intended Status updated on 27.03.2019
Former	Examination is in progress Status updated on 12.10.2018
Former	Request for examination was made Status updated on 14.09.2018
Former	The application has been published Status updated on 16.02.2018
Most recent event Tooltip	15.07.2022	Lapse of the patent in a contracting state New state(s): MK	published on 17.08.2022 [2022/33]
Applicant(s)	For all designated states OncoTherapy Science, Inc. 2-1, Sakado 3-Chome Takatsu-ku Kawasaki-shi Kanagawa 213-0012 / JP
	[2018/12]
Inventor(s)	01 / NAKAMURA, Yusuke The Institute of Medical Science The University of Tokyo 6-1 Shirokanedai 4-chome Minato-ku, Tokyo 108-8639 / JP
	02 / OSAWA, Ryuji Oncotherapy Science Inc. 2-1 Sakado 3-chome Takatsu-ku Kawasaki-shi, Kanagawa 213-0012 / JP
	03 / WATANABE, Tomohisa OncoTherapy Science Inc. 2-1, Sakado 3-chome Takatsu-ku Kawasaki-shi, Kanagawa 213-0012 / JP
	04 / NAKAYAMA, Gaku Oncotherapy Science Inc. 2-1 Sakado 3-chome Takatsu-ku Kawasaki-shi, Kanagawa 213-0012 / JP
	05 / TSUNODA, Takuya OncoTherapy Science Inc. 2-1, Sakado 3-chome Takatsu-ku Kawasaki-shi, Kanagawa 213-0012 / JP
	06 / YOSHIMURA, Sachiko OncoTherapy Science Inc. 2-1, Sakado 3-chome, Takatsu-ku Kawasaki-shi, Kanagawa 213-0012 / JP
	[2018/12]
Representative(s)	Zacco GmbH Bayerstrasse 83 80335 München / DE
	[2018/12]
Application number, filing date	17198358.8	25.10.2012
	[2018/12]
Priority number, date	US201161552817P	28.10.2011 Original published format: US 201161552817 P
	[2018/12]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP3296317
	Date:	21.03.2018
	Language:	EN
	[2018/12]
	Type:	B1 Patent specification
	No.:	EP3296317
	Date:	11.12.2019
	Language:	EN
	[2019/50]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	03.01.2018
Classification	IPC:	C07K7/06, A61K38/00, A61K48/00, A61P35/00, C07K16/18, C12N5/10, C12N15/09, G01N33/574, A61K39/00, C07K14/47, // C07K16/40, C12N9/12, G01N33/50	[2018/12]
	CPC:	G01N33/574 (EP,CN,US); A61K39/001162 (EP,CN,RU,US); C07K7/06 (CN,KR,RU,US); A61K38/00 (EP,CN,KR,US); A61K39/0005 (CN,US); A61K39/0011 (EP,CN,KR,RU,US); (+) A61K39/4611 (EP,CN,RU,US); A61K39/4644 (EP,CN,RU,US); A61K39/464462 (EP,CN,RU,US); A61P35/00 (EP); A61P37/04 (EP); C07K14/4748 (EP,CN,KR,US); C07K16/18 (CN,KR,US); C07K16/40 (CN,KR,US); C12N9/12 (EP,CN,US); C12N9/1205 (EP,CN,KR,US); C12Y207/12002 (EP,CN,KR,US); G01N33/505 (EP,CN,KR,US); A61K2039/5154 (KR); A61K2039/572 (CN,KR,US); A61K39/005 (RU); C07K2317/34 (CN,KR,US); C12N15/85 (RU); C12N5/0638 (EP,CN,RU,US) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/42]
Former [2018/12]	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Title	German:	TOPK-PEPTIDE UND IMPFSTOFFE DAMIT	[2018/12]
	English:	TOPK PEPTIDES AND VACCINES INCLUDING THE SAME	[2018/12]
	French:	PEPTIDES TOPK ET VACCINS LES COMPORTANT	[2018/12]
Examination procedure	25.10.2017	Date on which the examining division has become responsible
	11.09.2018	Amendment by applicant (claims and/or description)
	11.09.2018	Examination requested [2018/42]
	11.10.2018	Despatch of a communication from the examining division (Time limit: M04)
	16.01.2019	Reply to a communication from the examining division
	28.03.2019	Communication of intention to grant the patent
	28.05.2019	Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
	12.07.2019	Communication of intention to grant the patent
	31.10.2019	Fee for grant paid
	31.10.2019	Fee for publishing/printing paid
	31.10.2019	Receipt of the translation of the claim(s)
Parent application(s) Tooltip	EP12844519.4 / EP2771350
Opposition(s)	14.09.2020	No opposition filed within time limit [2020/47]
Fees paid	Renewal fee
	25.10.2017	Renewal fee patent year 03
	25.10.2017	Renewal fee patent year 04
	25.10.2017	Renewal fee patent year 05
	25.10.2017	Renewal fee patent year 06
	24.10.2018	Renewal fee patent year 07
	25.10.2019	Renewal fee patent year 08
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	25.10.2012
	AL	11.12.2019
	CY	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	MK	11.12.2019
	MT	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	TR	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
	[2022/33]
Former [2022/27]	HU	25.10.2012
	AL	11.12.2019
	CY	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	MT	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	TR	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2021/31]	AL	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2021/14]	AL	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2020/51]	AL	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2020/40]	AL	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2020/37]	AL	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	PT	06.05.2020
Former [2020/36]	AL	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	PT	06.05.2020
Former [2020/35]	AL	11.12.2019
	CZ	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
Former [2020/32]	AL	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	RS	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
Former [2020/25]	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	RS	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
Former [2020/23]	FI	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
Former [2020/22]	FI	11.12.2019
	LT	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
Former [2020/21]	NO	11.03.2020
Documents cited:	Search	WO2008018642 [ ] (ONCOTHERAPY SCIENCE INC [JP], et al);
		[A]EP1972639 (CELL SIGNALING TECHNOLOGY INC [US]);
		[XI]US2011229504 (FRITSCHE JENS [DE], et al);
	by applicant	JPS6317688
		US4722848
		US5108921
		US5545807
		US5545806
		US5569825
		US5580859
		US5589466
		US5625126
		US5633425
		US5661016
		US5679647
		WO9804720
		US5736524
		US5739118
		US5804566
		WO9903499
		US5922687
		JPH11510507
		WO9967288
		JP2000509281
		US6150584
		WO02072631
		WO03027322
		US2004209295
		WO2006031221
		WO2007032255

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p